LATS1 and neoplasm: Future therapeutic strategies could aim to restore tumor-suppressive inputs (e.g., by targeting FAT1-mediated signaling or GPCRs that activate LATS1/2) or directly inhibit the oncogenic YAP/TAZ-TEAD axis.